Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels
February 08 2024 - 8:00AM
Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage
biotechnology company dedicated to pioneering innovative cancer and
viral infection treatments, is pleased to announce the launch of a
new social media initiative to provide education and updates about
the company. Recognizing the importance of engaging with all
stakeholders, Indaptus will generate content on a variety of
digital platforms, including X (formerly known as Twitter) and
LinkedIn.
Indaptus Therapeutics emerges from over a century of
groundbreaking advancements in immunotherapy and has built an
approach that is designed to stimulate a broad acting effect on the
immune system to combat some of the most difficult types of cancer.
At the core of Indaptus' patented technology are single strains of
proprietary killed, non-pathogenic bacteria that can activate
cellular immune pathways in the fight against cancer and viral
infections. The company is currently advancing itsinnovative
immunotherapy for the treatment of solid metastatic tumors in Phase
1 human trials.
Jeffrey Meckler, Indaptus Therapeutics’ CEO, expressed
enthusiasm about this initiative, stating, "Our goal is not only to
advance groundbreaking treatments, but also to foster open
communication and education around our work. Social media provides
an ideal platform for connecting with a broader audience, sharing
insights, and building a community that is passionate about medical
advancements."
The launch of these channels signifies Indaptus Therapeutics'
commitment to transparency, knowledge-sharing, and a desire to stay
connected with its stakeholders. The company will utilize these
platforms to provide updates on its research, share educational
content about cancer immunotherapy, and offer a behind-the-scenes
look at its team and scientific progress. The company invites all
interested parties, including patients, researchers, and the
general public, to join the conversation and stay informed about
the company’s promising strides in cancer and viral infection
treatment.
Connect with Indaptus Therapeutics on:
X/(Twitter): @Indaptus
Linkedin:
https://www.linkedin.com/company/indaptus-therapeutics-inc/
About Indaptus TherapeuticsIndaptus
Therapeutics has evolved from more than a century of immunotherapy
advances. The Company’s novel approach is based on the hypothesis
that efficient activation of both innate and adaptive immune cells
and pathways and associated anti-tumor and anti-viral immune
responses will require a multi-targeted package of immune
system-activating signals that can be administered safely
intravenously (i.v.). Indaptus’ patented technology is composed of
single strains of attenuated and killed, non-pathogenic,
Gram-negative bacteria producing a multiple Toll-like receptor
(TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR)
and Stimulator of interferon genes (STING) agonist Decoy platform.
The product candidates are designed to have reduced i.v. toxicity,
but largely uncompromised ability to prime or activate many of the
cells and pathways of innate and adaptive immunity. Decoy product
candidates represent an antigen-agnostic technology that have
produced single-agent activity against metastatic pancreatic and
orthotopic colorectal carcinomas, single agent eradication of
established antigen-expressing breast carcinoma, as well as
combination-mediated eradication of established hepatocellular
carcinomas and non-Hodgkin’s lymphomas in standard pre-clinical
models, including syngeneic mouse tumors and human tumor
xenografts. In pre-clinical studies tumor eradication was observed
with Decoy product candidates in combination with anti-PD-1
checkpoint therapy, low-dose chemotherapy, a non-steroidal
anti-inflammatory drug, or an approved, targeted antibody.
Combination-based tumor eradication in pre-clinical models produced
innate and adaptive immunological memory, involved activation of
both innate and adaptive immune cells, and was associated with
induction of innate and adaptive immune pathways in tumors after
only one i.v. dose of Decoy product, with associated “cold” to
“hot” tumor inflammation signature transition. IND-enabling,
nonclinical toxicology studies demonstrated i.v. administration
without sustained induction of hallmark biomarkers of cytokine
release syndromes, possibly due to passive targeting to liver,
spleen, and tumor, followed by rapid elimination of the product.
Indaptus’ Decoy product candidates have also produced significant
single agent activity against chronic hepatitis B virus (HBV) and
chronic human immunodeficiency virus (HIV) infections in
pre-clinical models.
Forward-Looking Statement sThis press
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act. These include
statements regarding management’s expectations, beliefs and
intentions regarding, among other things: our expectations and
plans regarding our Phase 1 clinical trial of Decoy20, including
the timing and design thereof and our expectations regarding the
recommended Phase 2 doses for subsequent multi-dosing and
combination studies and related timing; the anticipated effects of
our product candidates, including Decoy20; the plans and objectives
of management for future operations; our research and development
activities and costs; the sufficiency of our cash and cash
equivalents to fund our ongoing activities and our cash management
strategy; and our assessment of financing options to support our
corporate strategy. Forward-looking statements can be identified by
the use of forward-looking words such as “believe”, “expect”,
“intend”, “plan”, “may”, “should”, “could”, “might”, “seek”,
“target”, “will”, “project”, “forecast”, “continue” or “anticipate”
or their negatives or variations of these words or other comparable
words or by the fact that these statements do not relate strictly
to historical matters. Because forward-looking statements relate to
matters that have not yet occurred, these statements are inherently
subject to risks and uncertainties that could cause our actual
results to differ materially from any future results expressed or
implied by the forward-looking statements. Many factors could cause
actual activities or results to differ materially from the
activities and results anticipated in forward-looking statements,
including, but not limited to the following: our limited operating
history; conditions and events that raise substantial doubt
regarding our ability to continue as going concern; the need for,
and our ability to raise, additional capital given our lack of
current cash flow; our clinical and preclinical development, which
involves a lengthy and expensive process with an uncertain outcome;
our incurrence of significant research and development expenses and
other operating expenses, which may make it difficult for us to
attain profitability; our pursuit of a limited number of research
programs, product candidates and specific indications and failure
to capitalize on product candidates or indications that may be more
profitable or have a greater likelihood of success; our ability to
obtain and maintain regulatory approval of any product candidate;
the market acceptance of our product candidates; our reliance on
third parties to conduct our preclinical studies and clinical
trials and perform other tasks; our reliance on third parties for
the manufacture of our product candidates during clinical
development; our ability to successfully commercialize Decoy20 or
any future product candidates; our ability to obtain or maintain
coverage and adequate reimbursement for our products; the impact of
legislation and healthcare reform measures on our ability to obtain
marketing approval for and commercialize Decoy20 and any future
product candidates; product candidates of our competitors that may
be approved faster, marketed more effectively, and better tolerated
than our product candidates; our ability to adequately protect our
proprietary or licensed technology in the marketplace; the impact
of, and costs of complying with healthcare laws and regulations,
and our failure to comply with such laws and regulations;
information technology system failures, cyberattacks or
deficiencies in our cybersecurity; and unfavorable global economic
conditions. These and other important factors discussed under the
caption “Risk Factors” included in our Quarterly Report on Form
10-Q for the quarter ended September 30, 2023 filed with the SEC on
November 6, 2023, our most recent Annual Report on Form 10-K filed
with the SEC on March 17, 2023, and our other filings with the SEC,
could cause actual results to differ materially from those
indicated by the forward-looking statements made in this press
release. All forward-looking statements speak only as of the date
of this press release and are expressly qualified in their entirety
by the cautionary statements included in this press release. We
undertake no obligation to update or revise forward-looking
statements to reflect events or circumstances that arise after the
date made or to reflect the occurrence of unanticipated events,
except as required by applicable law.
Contact:
Indaptus Therapeutics:
investors@indaptusrx.com
Investor Relations Contact: CORE IR Louie Toma
louie@coreir.com
Media Contact: CORE IR
Jules Abraham julesa@coreir.com 917-885-7378
Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From Sep 2024 to Oct 2024
Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From Oct 2023 to Oct 2024